B7‑H3(also known as CD276)

B7-H3 is a type I transmembrane protein belonging to the B7 family of co-stimulatory proteins. B7-H3 is mostly expressed on professional APCs including B cells, macrophages, and dendritic cells at low levels. It is detected on various human and murine tumor cells, nasal and airway epithelial cells. Its expression on dendritic cells appears to be up-regulated by LPS.

1353485-38-7
MGA271
1353485-38-7

Background


Structure and Biological function of B7-H3

B7-H3, also known as CD276, is a molecule of immunological checkpoint in the B7-CD28 family. B7-H3 is similar to the extracellular domain of programmed death receptor 1, consisting of two immunoglobulin constant and variable domains. They are all expressed in malignant tumors, and are related to the growth, metastasis, recurrence and poor prognosis of malignant tumors. At the same time, B7-H3 is not only a kind of CO stimulator in malignant tumor, but also has a co-inhibitory effect on the regulatory T cells (Treg).

B7-H3 and non-small cell lung cancer(NSCLC)

B7-H3 was expressed in 6 different non-small cell lung cancer fine cell lines. It is found that B7-H3 epidermis is obviously related to the Lymphoma transition of NSCLC, and that B7-H3 can inhibit the immune system of NSCLC. B7-H3 may be a latent marker of invasion and translocation of NSCLC. A large number of beds are needed to prove it.

B7-H3 and mammary gland carcinoma

So far, breast adenoma is the highest rate of female sex diagnosis in the world the highest abnomal B7-H3 in breast adenocarcinoma. B7-H3 can inhibit fine cell viability and colonization in small cells of breast adenocarcinoma with low B7-H3 level, whereas in high-epidermal B7-H3, it can inhibit fine cell viability and colonization of breast carcinoma. In the cell, not only the growth energy of fine cells is increased, but also the ability of trasilibin is lowered. And the drug effect of everolimus on cancer. In future research, B7-H3 target drugs can be made for anticancer treatment.

Anti B7-H3 therapy

The treatment of blocking B7-H3 and combined therapy with chemical therapy is a kind of treatment with front view. The anti-tumor effect of Enoblituzumab (MGA271) was mediated by the cytotoxicity mediated by antibody dependent cells (ADCC). The monoclonal antibody 8H9 targeting B7-H3 was successfully used in the clinical treatment of metastatic neuronal tumors. There will be more clinical research on the B7-H3 sub-quadrate in the absence of the target, which will provide a better treatment for tumour.

BOC Sciences is pleased to provide you with excellent B7-H3 target drug related services. The company has the world's leading pharmaceutical and biotechnology R&D laboratory. Over the years, our experts have been working on the development of targeted B7-H3 therapy, and achieved good results. The company sincerely looks forward to working with you hand in hand.

Reference:

Wang Mingdian, Zhang Daxin.(2018).Research Progress of B7-H3 in malignant tumor.Journal of Modern Oncology.26(14);2305-2308.